Here are the DEF 14A proxy statements from Century Therapeutics, Inc. (IPSC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow IPSC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IPSC filings page.
Century Therapeutics, Inc. is holding its 2026 annual stockholders meeting virtually on June 11, 2026 at 9:00 a.m. Eastern Time. Stockholders of record on April 16, 2026, when 180,354,197 common shares were outstanding, can vote online.
Key items include electing two Class II directors through 2029, ratifying Ernst & Young LLP as independent auditor for 2026, and approving an amendment to increase authorized common stock from 300,000,000 to 450,000,000 shares, plus a related adjournment proposal. The proxy also outlines board independence and committee structure, recent R&D milestones in cell therapies, a January 2026 securities purchase agreement with approximately $135 million in gross proceeds, and detailed 2025 executive and director compensation, including a $2.38 million total package for the CEO.